BridgeBio Oncology Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | — | $121.2M | $73.1M | — |
| SG&A Expense | — | $24.6M | $7.8M | $41.7K |
| Operating Income | — | $-145.8M | $-80.9M | $-41.7K |
| Operating Margin | — | — | — | — |
| Interest Expense | — | — | — | — |
| Pretax Income | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | — |
| Net Income | — | $-134.0M | $-74.3M | $-41.7K |
| Net Margin | — | — | — | — |
| EPS (Basic) | — | $-4.30 | $-2.38 | — |
| EPS (Diluted) | — | $-4.30 | $-2.38 | — |
| Shares Outstanding (Basic) | 80.0M | 31.1M | 31.1M | — |
| Shares Outstanding (Diluted) | 80.0M | 31.1M | 31.1M | — |
| Dividends Per Share | — | — | — | — |